

October 17, 2016



# Trevena to Webcast Thought Leader Symposium on Acute Pain Management and Present at the 2016 Annual Meeting of the American Society of Anesthesiologists

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will give two oral presentations at the 2016 Annual Meeting of the American Society of Anesthesiologists being held at McCormick Place in Chicago, Illinois, on October 22-26, 2016. Both presentations will highlight Phase 2 data on oliceridine, Trevena's Breakthrough Therapy-designated lead product candidate being developed as a first line intravenously-administered treatment for patients experiencing moderate-to-severe acute pain.

In parallel to the conference, the company will be webcasting a thought leader symposium that will discuss unmet needs associated with current injectable analgesics and how oliceridine may fit into the current treatment landscape for acute moderate to severe pain. The webcast will begin at 5:00 p.m. EDT (4:00 p.m. CDT) on Monday, October 24.

To access the live audio webcast of the thought leader symposium, please visit the "Investors" section of the company's website at [www.trevena.com](http://www.trevena.com). Following the conclusion of the presentation, the webcast will be archived for 30 days.

The company also is sponsoring an accredited continuing medical education (CME) symposium entitled "Gaining Insight into Emerging Pain Management Therapies in an Acute Setting" that will review current and new acute pain management therapies.

Details for the conference events are as follows:

## Oral presentations

|                              |  |
|------------------------------|--|
| <b>Title:</b>                | Rapid Onset of Pain Relief With Oliceridine (TRV130), a Novel $\mu$ -GPS, Versus Morphine                          |
| <b>Presenter:</b>            | Eugene R. Viscusi, M.D., Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University |
| <b>Presentation number:</b>  | A5037  |
| <b>Presentation session:</b> | OR16-1: Regional Anesthesia and Acute Pain, October 26, 2016, 9:45 – 11:15 a.m. CT                                 |

**Title:** Duration of PCA Interruptions with Oliceridine (TRV130), a novel  $\mu$ -GPS, vs. Morphine  
**Presenter:** Jianguo Cheng, M.D., Ph.D, Professor of Anesthesiology, Case Western Reserve University  
**Presentation number:** A5037  
**Presentations session:** OR16-1: Regional Anesthesia and Acute Pain, October 26, 2016, 9:45 – 11:15 a.m.

### **Thought leader symposium**

**Title:** Oliceridine and Unmet Needs in Injectable Analgesia  
**Presenters:** David Soergel, M.D., Chief Medical Officer, Trevena  
Keith Candiotti, M.D., Professor of Anesthesiology and Internal Medicine, University of Miami School of Medicine, Florida  
Timothy Beard, M.D., FACS, Chair of Department of Surgery, Bend Memorial Clinic, Oregon  
Eric Lavonas, M.D., FACEP, Professor of Emergency Medicine, University of Colorado School of Medicine, Colorado; past Chair of the Pharmacy & Therapeutics Committee, Denver Health and Hospital Authority  
Carrie Bourdow, Chief Commercial Officer, Trevena  
**Time:** 5:00 – 7:00 p.m. EDT (4:00 – 6:00 p.m. CDT)

### **Accredited Satellite Symposium**

**Title:** Gaining Insight into Emerging Pain Management Therapies in an Acute Setting  
**Time and location:** Hyatt Regency Chicago, Regency Ballroom CD, October 24, 2016, 6:00 – 8:00 a.m. CT

### **About Trevena**

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Oliceridine (TRV130), Trevena's lead product candidate, is the first pain program granted Breakthrough Therapy designation by the U.S. Food & Drug Administration and is in Phase 3 development for intravenous management of moderate to severe acute pain. In Phase 2b, intravenous oliceridine demonstrated rapid and powerful analgesic efficacy with fewer opioid-related adverse events including nausea, vomiting, and respiratory events compared to intravenous morphine, thus offering a promising safety and tolerability profile compared to conventional opioid analgesics while providing powerful pain relief to patients.

### **Cautionary Note on Forward Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company's clinical trials; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials; expectations for regulatory approvals; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company's intellectual property; other matters that could affect the availability or commercial potential of the Company's therapeutic candidates, including how oliceridine may fit into the current treatment landscape for acute moderate to severe pain; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20161017006477/en/>

**Investor Contact:**

Trevena, Inc.

Jonathan Violin, Ph.D.

Sr. director of investor relations

610-354-8840 x231

[jviolin@trevena.com](mailto:jviolin@trevena.com)

or

**Media Contact:**

Trevena, Inc.

Public Relations

[PR@trevena.com](mailto:PR@trevena.com)

Source: Trevena, Inc.